Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands Alexion’s metabolic franchise wi

First Page		Document Content
Date: 2015-05-06 06:45:36 Alexion Pharmaceuticals Eculizumab Drug discovery Paroxysmal nocturnal hemoglobinuria Clinical trial Glycogen storage disease type II Health Medicine Rare diseases		Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands Alexion’s metabolic franchise wi Add to Reading List Source URL: www.alexion-synagevatransaction.com Download Document from Source Website File Size: 444,87 KB Share Document on Facebook

	Alexion Pharmaceuticals, Inc. One of the best things I like about Everbridge is incorporating the DocID: 1oLjC - View Document
	L’Institut Imagine choisi pour accueillir le premier centre de recherche et développement d’Alexion Pharmaceuticals en Europe Paris, 22 janvier 2015 Le laboratoire américain Alexion, spécialisé dans le traitement DocID: 1e8bf - View Document
	Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands Alexion’s metabolic franchise wi DocID: 19nD4 - View Document
	PDF Document DocID: 16wNC - View Document
	PDF Document DocID: 16lwK - View Document